Podcasts about cognitive impairment

In his weekly clinical update, Dr. Griffin with Vincent Racaniello debate the changes in FDA vaccine approval policy especially how it is applied to COVID-19 vaccines and restricts vaccine availability/usage and Novavax's vaccine, mpox on surfaces and in the air, “bird flu”, the ongoing measles outbreak globally before Dr. Griffin reviews recent statistics on RSV, benefits of vaccination for infants, influenza and SARS-CoV-2 infections, the Wasterwater Scan dashboard, the high number of childhood deaths during this “flu” season, the May 22 VRBPAC COVID-19 vaccine meeting, where to find PEMGARDA, prolonged steroid and antibiotic therapies, provides information for Columbia University Irving Medical Center's long COVID treatment center, where to go for answers to your long COVID questions, cognitive impairment in long COVID and contacting your federal government representative to stop the assault on science and biomedical research. Subscribe (free): Apple Podcasts, RSS, email Become a patron of TWiV! Links for this episode FDA to issue new vaccine approval guidance amid questions over coronavirus shots (Washington Post) FDA vaccine committee meeting(Reuters) Evidence-based approach to COVID-19 vaccination (NEJM) FDA CBER townhall: new COVID019 vaccination approval mechanism (YouTube) FDA poised to restrict access to COVID vaccines, our own Dr. Griffin is cited! (NY Times) Novavax approval letter (FDA) We giveth and taketh away: Novavax approved but restricted use (AP News) FDA approves Novavax COVID vaccine with stricter new conditions (NY Times) History behind public health falsehoods– vaccine and autism (NPR) Making vaccines less accessible-RFK Jr making MAHA! (PBS News Hour) Kenneday says DO NOT to take medical advice from him, the HHS secretary…hummmm (NY Times) Staying up to date with COVID-19 vaccines (CDC: COVID-19) How science lost America's trust and surrendered health policy to skeptics (WSJ) HHS stops recommendation of COVID-19 shots for children and pregnant women (Reuters) No more routine COVID-19 vaccines for children and pregnant women (WSJ) House to investigate Pfizer for allegedly delaying COVID-19 vaccines (Reuters) Statement on the antigen composition of COVID-19 vaccines (WHO) WHO advisers say current strains OK for COVID vaccine production (CIDRAP) We can't remain indifferent to suffering: Catholic Church now champions HPV vaccination (DailyNation) Air and surface sampling for mpox in UK (Eurosurveillance) Researchers report mpox DNA, live virus on surfaces and in air from patients' rooms(CIDRAP) USDA reported H5N1 bird flu detection in wild birds (CDC: Avian Influenza) USDA reported H5N1 in poultry (CDC: Avian Influenza) HPAI Confirmed Cases in Livestock(USDA Animal and Plant Health Inspections Service) H5 bird flu: current situation (CDC: Avian Influenza) Bird flu (CDC: Avian Influenza) Measles cases and outbreaks (CDC Rubeola) Measles and rubella weekly monitoring report: (Government of Canada) Measles vaccine recommendations from NYP (jpg)  Get the FACTS about measles (NY State Department of Health) Measles (CDC Measles (Rubeola) Measles vaccine (CDC Measles (Rubeola) Presumptive evidence of measles immunity (CDC) Contraindications and precautions to measles vaccination (CDC) Adverse events associated with childhood vaccines: evidence bearing on causality (NLM) Measles Vaccination: Know the Facts(ISDA: Infectious Diseases Society of America) Deaths following vaccination: what does the evidence show (Vaccine) Influenza: Waste water scan for 11 pathogens (WastewaterSCan) US respiratory virus activity (CDC Respiratory Illnesses) Weekly surveillance report: clift notes (CDC FluView) Respiratory virus activity levels (CDC Respiratory Illnesses) Weekly surveillance report: clift notes (CDC FluView) FDA-CDC-DOD: 2025-2046 influenza vaccine composition (FDA) RSV: Waste water scan for 11 pathogens (WastewaterSCan) US respiratory virus activity (CDC Respiratory Illnesses) RSV-Network (CDC Respiratory Syncytial virus Infection) Waste water scan for 11 pathogens (WastewaterSCan) COVID-19 deaths (CDC) COVID-19 national and regional trends (CDC) COVID-19 variant tracker (CDC) SARS-CoV-2 genomes galore (Nextstrain) Interim Clinical Considerations for Use of COVID-19 Vaccines in the United States (CDC: COVID-19) COVID-19 vaccine VRBPAC May 22 (FDA) Where to get pemgarda (Pemgarda) EUA for the pre-exposure prophylaxis of COVID-19 (INVIYD) Infusion center (Prime Fusions) CDC Quarantine guidelines (CDC) NIH COVID-19 treatment guidelines (NIH) Drug interaction checker (University of Liverpool) Infectious Disease Society guidelines for treatment and management (ID Society) Molnupiravir safety and efficacy (JMV) Convalescent plasma recommendation for immunocompromised (ID Society) What to do when sick with a respiratory virus (CDC) When your healthcare provider is infected/exposed with SARS-CoV-2 (CDC) Managing healthcare staffing shortages (CDC) Steroids,dexamethasone at the right time (OFID) The clinical impact of prolonged steroid therapy in severe COVID-19 patients (BMC Pulmonary Medicine) Anticoagulation guidelines (hematology.org) Antibiotic Treatment in Patients Hospitalized for Nonsevere COVID-19 (JAMA Network Open) Daniel Griffin's evidence based medical practices for long COVID (OFID) Long COVID hotline (Columbia : Columbia University Irving Medical Center) The answers: Long COVID Self-reported health, neuropsychological tests and biomarkers in fully recovered COVID-19 patients vs patients with post-COVID cognitivesymptoms (PLoS One) Vortioxetine for Cognitive Impairment in Major Depressive Disorder During Post-COVID Syndrome (Journal of Clincial Psychiatrist) Reaching out to US house representative Letters read on TWiV 1220 Dr. Griffin's COVID treatment summary (pdf) Timestamps by Jolene Ramsey. Thanks! Intro music is by Ronald Jenkees Send your questions for Dr. Griffin to daniel@microbe.tv Content in this podcast should not be construed as medical advice.

God's Debris: The Complete Works, Amazon https://tinyurl.com/GodsDebrisCompleteWorksFind my "extra" content on Locals: https://ScottAdams.Locals.comContent:Politics, David Packard, President Trump, One Guy Problem, Israel Embassy Terror Attack, Biden's Cognitive Impairment, Joe Scarborough, Jake Tapper, Autopen Whistleblower, National Debt Crisis, President Ramaphosa, South Africa, Anti-Boer Chant, Anti-White Farmer Chant, Grok, Elon Musk, Anti-Musk Atlantic Article, President Putin, Ukraine War Options, Golden Dome, Transactional World, French Laser Rifle, North Korean Warship Capsizes, Scott Adams~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~If you would like to enjoy this same content plus bonus content from Scott Adams, including micro-lessons on lots of useful topics to build your talent stack, please see scottadams.locals.com for full access to that secret treasure.

Dr. Chris Winfrey practices neuropsychiatry in private practice at New Image Wellness, in Marlton, NJ. His practice is a blend of orthomolecular psychiatry, functional medicine, and psychoanalytic therapy. He uses this combination of medicine towards conditions such as Traumatic Brain Injuries, Cognitive Impairment, PANDAS, Mold Toxicity induced Encephalitis, refractory depression, complex PTSD and other conditions to rehabilitate the brain and restore mental functioning. Key Topics: - What conventional psychiatry is missing right now - How thyroid plays a role in energy and why simply taking your temp daily could make a difference - The connection between mitochondrial function and brain health - How your overall toxic load is hindering your mental wellness - PH balance: the nutrition puzzle piece we often miss - Mold toxicity and its impact on mental health - ADHD is more than just a dopamine issue - Lyme disease and the psychological impact of vector-borne disease Learn more about Dr. Winfrey at https://drchriswinfrey.com/ and newimagewellness.net Join Erin's monthly mailing list to get health tips and fresh meal plans and recipes every month: https://mailchi.mp/adde1b3a4af3/monthlysparksignup Preorder Erin's new book, Live Beyond Your Label, at erinbkerry.com/upcomingbook/

Leah explores the potential connection between Alzheimer's disease and tinnitus in veterans, highlighting how both conditions—often overlooked as related—may actually share neurological links. Drawing from multiple scientific studies, Leah presents compelling evidence that tinnitus could be an early indicator or risk factor for cognitive decline and neurodegenerative diseases like Alzheimer's and Parkinson's, especially in veterans exposed to chronic stress and noise. She emphasizes the importance of discussing symptoms with medical providers and seeking support through accredited VA claims professionals, especially in complex disability cases.

- Broadcast News Introduction and Upcoming Segments (0:00) - AI Advancements and Their Impact on Jobs (0:45) - Breaking News: Trump-China Trade Deal and Its Implications (2:46) - Pakistan-India Cyber War and Its Potential Escalation (9:55) - Power Grid Vulnerabilities and Preparedness (13:36) - Crypto Wallets and the Importance of Self-Custody (19:04) - AI Capabilities and Their Implications for Human Jobs (25:14) - The Role of Enoch AI in Empowering Users (59:30) - The War on Human Cognition and Its Vectors (1:05:29) - Strategies for Protecting Cognitive Function (1:21:34) - Chemotherapy and Cognitive Impairment (1:21:56) - Natural Light and Sun Exposure (1:25:06) - Media and Information Warfare (1:30:33) - Societal and Behavioral Factors (1:33:37) - Defending Against Environmental Toxins (1:41:05) - Nutritional and Dietary Factors (1:47:00) - Pharmaceutical and Medical Warfare (1:49:22) - EMF Exposure and Technological Risks (1:59:51) - Information Warfare and Censorship (2:02:12) - Societal and Behavioral Factors (2:11:11) - Zionist and Chinese Strategic Moves in the Middle East (2:25:45) - Trump's Arrogance and Military Presence in Panama (2:26:04) - China's Influence and Economic Strategy in Panama (2:26:21) - Strategic Importance of the Panama Canal (2:52:23) - Strait of Hormuz and Global Energy Supply (3:06:20) - US-China Trade War and Economic Implications (3:14:03) - Anthropological Warfare and Cultural Resilience (3:14:21) - Migration and Demographic Warfare (3:22:15) - Global Economic and Political Dynamics (3:28:51) - Future Strategic Moves and Predictions (3:33:17) For more updates, visit: http://www.brighteon.com/channel/hrreport NaturalNews videos would not be possible without you, as always we remain passionately dedicated to our mission of educating people all over the world on the subject of natural healing remedies and personal liberty (food freedom, medical freedom, the freedom of speech, etc.). Together, we're helping create a better world, with more honest food labeling, reduced chemical contamination, the avoidance of toxic heavy metals and vastly increased scientific transparency. ▶️ Every dollar you spend at the Health Ranger Store goes toward helping us achieve important science and content goals for humanity: https://www.healthrangerstore.com/ ▶️ Sign Up For Our Newsletter: https://www.naturalnews.com/Readerregistration.html ▶️ Brighteon: https://www.brighteon.com/channels/hrreport ▶️ Join Our Social Network: https://brighteon.social/@HealthRanger ▶️ Check In Stock Products at: https://PrepWithMike.com

In this episode, Dr. Rob Whitfield, a board-certified plastic surgeon, sits down with Dr. Esra Cavusoglu, a psychologist and certified addiction therapist, to chat about how addiction, hormone health, and overall wellness all connect. Dr. Whitfield dives into the topic of breast implant illness, going over its symptoms and the different treatment options available, while emphasizing the importance of a multimodal approach to managing pain after surgery. Dr. Cavusoglu shares her unique methods for treating addiction, focusing on how hormone imbalances and trauma play a role. Tune in to hear more about the need for a holistic approach to health, integrating both physical and mental health care to boost patient outcomes and enhance overall well-being. Connect with Dr. Esra Cavusoglu Instagram (https://www.instagram.com/esracavusoglu/reels/) LinkedIn (http://linkedin.com/in/esra-m-cavusoglu-phd-casac-cac-77548021) Website (https://www.longevilab.com/en/c/longevity) Show Highlights: Discussion on Cognitive Impairment (00:02:20) Cognitive impairment and its relevance in addiction treatment Unique Methods in Addiction Treatment (00:02:58) Treating addiction through hormone level assessments and comprehensive bloodwork Pain Management Post-Surgery (00:10:12) Strategies for managing pain and avoiding opioid dependence after surgery High-Performance Addiction (00:14:22) Addiction patterns in high-functioning individuals and their coping mechanisms Young Patient Demographics (00:19:03) Rising rates of eating disorders and alcoholism among younger patients Body Dysmorphia Concerns (00:20:21) Prevalence of body dysmorphia and early cosmetic procedures in young women Recognizing Addiction in Loved Ones (00:28:42) Identifying addiction through behavioral changes rather than substance use frequency Bio: Dr. Cavusoglu Trained both in the United States and internationally, Dr. Esra Çavuşoğlu is a doctor in psychology and a certified addiction therapist in the State of New York. She formerly held a position on the Clinical Advisory Board of the Yale University School of Medicine and served as an Advisor for International Development with the Yale Program on Supervision. Dr. Esra Çavuşoğlu has participated in numerous international medical conferences and events. Some of the prominent organizations include serving as a moderator at the event organized by the United Nations Office on Drugs and Crime (UNODC) in Vienna, Austria, in 2016. Dr. Çavuşoğlu also acted as a panelist at the Asia Pacific Behavioral and Addiction Medicine (APBAM) Conference held in Singapore in 2013. Dr. Çavuşoğlu continues to treat her patients. In her capacity as the senior supervisor at the Oya Bahadır Yüksel Rehabilitation Center in Gaziantep, Turkey, Dr. Esra Çavuşoğlu designed and implemented the Turkey Model of Rehabilitation, which has since become the standard in the country. Prior to this role, she served for two years as the Vice President of Operations at the Gaziantep Center, where she collaborated closely with key Turkish government and health consultancy officials. She has made significant contributions to the field of addiction treatment in Turkey. Her articles on this topic have been honored with Presidential Recognition. She has presented on important subjects such as adolescent substance abuse treatment, including engagements in the United States, Turkey, and Singapore. Dr. Çavuşoğlu established the Contemporary Addiction Studies Association (ÇABAÇAD) to combat the growing addiction problem of Turkiye. In her power, her desire is to spread the science of addiction to the field and support institutions that are in need of building residential and outpatient programs, as well as create training curricula. Links and Resources Let's Connect Podcast: https://podcasts.apple.com/gb/podcast/breast-implant-illness/id1678143554 Spotify: https://open.spotify.com/show/1SPDripbluZKYsC0rwrBdb?si=23ea2cd9f6734667 TikTok: https://www.tiktok.com/@drrobertwhitfield?t=8oQyjO25X5i&r=1 IG: https://www.instagram.com/breastimplantillnessexpert/ FB: https://www.facebook.com/DrRobertWhitfield Linkedin: https://www.linkedin.com/in/dr-robert-whitfield-md-50775b10/ X: https://x.com/rob_whitfieldmd Read this article - https://www.breastcancer.org/treatment/surgery/breast-reconstruction/types/implant-reconstruction/illness/breast-implant-illness Shop: https://drrobssolutions.com SHARP: https://www.harp.health NVISN Labs - https://nvisnlabs.com/ Get access to Dr. Rob's Favorite Products below: Danger Coffee - Use our link for mold free coffee - https://dangercoffee.com/pages/mold-free-coffee?ref=ztvhyjg JASPR Air Purifier - Use code DRROB for the Jaspr Air Purifier - https://jaspr.co/ Echo Water - Get high quality water with our code DRROB10 - https://echowater.com/ BallancerPro - Use code DRROBVIP for the world's leader in lymphatic drainage technology - https://ballancerpro.com Ultrahuman - Use code WHITFIELD10 for the most accurate wearable - https://www.ultrahuman.com/ring/buy/us/?affiliateCode=drwhitfield

Dr. Chris Winfrey is a neuropsychiatrist at New Image Wellness in Marlton, NJ, where he integrates orthomolecular psychiatry, functional medicine, and psychoanalytic therapy. His expertise includes treating Traumatic Brain Injuries, Cognitive Impairment, PANDAS, Mold Toxicity-induced Encephalitis, refractory depression, and complex PTSD. He also has a deep interest in racial and cultural psychiatry, theology, and faith, aiming to bridge gaps between psychiatry and faith communities. Dr. Winfrey is currently exploring the psychosomatic and somatopsychic impact of microbial and toxic influences in neuropsychiatric conditions. Key Takeaways from the Interview Limitations of Traditional Psychiatric Training: Traditional psychiatric training focuses on acute management, effective for stabilization but not long-term healing. Dr. Winfrey realized his training was inadequate for addressing complex chronic illnesses. Discovering the Mind-Body Connection: Every psychological and psychiatric condition has a physiological foundation. Dr. Winfrey believes psychological disturbances often stem from physiological issues, with potential spiritual and energetic components. Transitioning to a Holistic Approach: Attending the ILADS conference helped Dr. Winfrey expand his diagnostic and treatment toolbox. His approach now considers biological, environmental, lifestyle, and psychosocial factors in patient care. Treating Chronic, Complex Patients: 100% of Dr. Winfrey's chronic patients present with microbial infections. His treatment protocol includes psychopharmacological agents, herbal treatments, supplements, lifestyle changes, and nutritional adjustments. Resources & Links: Follow the latest ILADS updates at ILADS.org Learn more about Dr. Winfrey Stay connected with Tick Boot Camp: Website | Instagram | Facebook | YouTube | TikTok | Twitter (X)

In this fascinating episode of the RWS Clinician's Corner, we do a deep dive into all things blood sugar with diabetes expert, Dr. Beverly Yates. We discuss how proper blood sugar handling is one of the body's topmost priorities, and how dysregulated blood sugar levels have far-reaching implications on the body and mind. Her commitment to advancing knowledge in the field underscores her passion for addressing complex health challenges and delivering impactful results for her clients.   In this interview, we explore:    -The paramount importance of blood sugar regulation in preventing all manner of chronic disease   -A closer look at Advanced Glycation End-products (AGEs)   -The significance of advanced lab markers in nutrition practice - what markers most practitioners miss and how to use the information gleaned from these to get even better results with your clients    -Practical strategies to enroll your clients in the lifestyle/behavior changes that are so essential to this process    Connect with Dr. Yates: Website: https://naturalhealthcare.com Instagram:  https://instagram.com/drbeverlyyates    YouTube Channel: https://www.youtube.com/c/DrBeverlyYates   Facebook: https://www.facebook.com/drbeverlyyates/   LinkedIn: https://www.linkedin.com/in/womenshealthexpert/    Timestamps: 00:00 Dr. Yates: Diabetes Program Innovator 09:45 Reconnecting with Estranged Father 11:31 "Clinicians Corner: Transformative Health Training" 19:32 Diet Challenges in Silicon Valley 23:14 "Personalizing Diet with CGM" 28:01 Intermittent Fasting & Carb Dependency 33:01 Blood Sugar Crashes and AGEs 41:39 Monitoring Metabolic Health Insights 45:30 Appetite Hormones and GLP1 Benefits 51:33 Genetic Discovery in Heart Health 58:00 Why Mimic Meat in Vegan Diets? 01:00:24 CGMs Reveal Oatmeal Intolerance 01:05:13 "Clinician's Corner: Episode Highlights"   Speaker bio:    Dr. Beverly Yates ND, is a licensed Doctor of Naturopathic Medicine. She is the nation's leader in online type 2 diabetes care – and she is on a mission to help 3 million people heal from type 2 diabetes and prediabetes. She used her background in MIT Electrical Engineering and work as a Systems Engineer in Silicon Valley to create effective online programs for people with diabetes to achieve blood sugar control and live the life they love.   Dr. Yates is an internationally recognized speaker and expert in diabetes and heart disease. She is a published author of Heart Health for Black Women: A Natural Approach to Healing and Preventing Heart Disease, and co-author of multiple books, including with Jack Canfield, The Soul of Success, Vol. 2. She is writing a new book on type 2 diabetes and prediabetes, based on her Yates Protocol, focusing on 5 Practical, Enjoyable Steps to Reversing Type 2 and Prediabetes and Living the Life You Love. Dr. Yates has been featured in numerous media outlets, including ABC, CBS, NBC, PBS, NPR, Black News Channel, Fox, Sirius XM, MindBodyGreen, Essence Magazine, Good Housekeeping, Women's World, Readers Digest, Rodale Press, and more. Keywords:   Restorative Wellness, Blood Sugar, Type 2 Diabetes, Pre Diabetes, CGM (Continuous Glucose Monitor), Nutrition, Meal Timing, Stress Management, Sleep Quality, Exercise, Glycemic Control, Advanced Glycation End Products (AGEs), Fasting, Insulin Sensitivity, Metabolic Health, Heart Disease, Cognitive Impairment, Plant-based Diet, Supplements, D Ribose, Resveratrol, Ubiquinol, Hemoglobin A1C, Fasting Insulin, C Peptide, Fructosamine, Leptin, Vegetarian Diet, Vegan Diet, Chronic Illness   Disclaimer: The views expressed in the RWS Clinician's Corner series are those of the individual speakers and interviewees, and do not necessarily reflect the views of Restorative Wellness Solutions, LLC. Restorative Wellness Solutions, LLC does not specifically endorse or approve of any of the information or opinions expressed in the RWS Clinician's Corner series. The information and opinions expressed in the RWS Clinician's Corner series are for educational purposes only and should not be construed as medical advice. If you have any medical concerns, please consult with a qualified healthcare professional. Restorative Wellness Solutions, LLC is not liable for any damages or injuries that may result from the use of the information or opinions expressed in the RWS Clinician's Corner series. By viewing or listening to this information, you agree to hold Restorative Wellness Solutions, LLC harmless from any and all claims, demands, and causes of action arising out of or in connection with your participation. Thank you for your understanding.  

In this episode of The Scope of Things, host Deborah Borfitz covers the latest news, including setting expectations for Phase II cancer trials, key learnings about dementia from the Nun Study, links between cardiovascular disease and mild cognitive impairment, using aspirin to prevent cancer spread, a clinical trial map to improve study access, and a naturally occurring molecule that rivals Ozempic in its weight loss potential. Deborah also speaks with Ravi Parikh, medical director of data and technology applications shared resource at Winship Cancer Institute of Emory University, about a novel AI platform he helped develop to translate clinical trial results to real world populations. News Roundup Phase 2 cancer drug trials Study in the Journal of the National Cancer Institute   Nun Study insights Review article in Alzheimer's & Dementia  DORIAN GRAY project Press release by the European Society of Cardiology Aspirin for preventing cancer spread Study in Nature  New clinical trial map  News announcement on the EMA website Molecule rivaling Ozempic Study in NatureThe Scope of Things podcast explores clinical research and its possibilities, promise, and pitfalls. Clinical Research News senior writer, Deborah Borfitz, welcomes guests who are visionaries closest to the topics, but who can still see past their piece of the puzzle. Focusing on game-changing trends and out-of-the-box operational approaches in the clinical research field, the Scope of Things podcast is your no-nonsense, insider's look at clinical research today.

Join host Kirk Buchner and guest journalist/filmmaker Kevin Patrick Allen in this in-depth episode of The Buck Stops Here as they explore the complex and untold story of Jim Tyrer—once among the very best offensive linemen who never made it into the Pro Football Hall of Fame. In their candid conversation, they cover everything from Tyrer's tragic off-field events and evolving discussions on concussions and CTE, to the investigative breakthroughs behind Kevin's upcoming documentary Beneath the Shadow. They also delve into the support system around Tyrer's family, the intricacies of the Hall of Fame voting process, and the challenges of untangling myth from fact. This episode is a must-watch for football history enthusiasts and anyone interested in the real stories behind the legends.You can see more about Kevin Patrick Allen's documentary *Beneath the Shadow* at this link: https://www.kppllc.net/beneath-the-shadow/- **0:00 – Introduction & Welcome** Kirk kicks off the episode and introduces the special guest, Kevin Patrick Allen.- **0:40 – Kevin's Background** Kevin shares insights into his journey as a journalist and filmmaker, shaped by his unique upbringing.- **1:30 – The Controversial Legacy of Jim Tyrer** The conversation turns to Jim Tyrer—his stellar career, the tragic events surrounding his life, and how it impacted his Hall of Fame eligibility.- **3:30 – New Perspectives on Concussions & CTE** Kirk and Kevin discuss how evolving research into concussions and CTE has reshaped our understanding of Tyrer's fate.- **4:20 – Investigative Breakthroughs & Evidence** Kevin explains his in-depth investigation, revealing that 90% of the key evidence was uncovered, which dramatically changed the narrative.- **5:00 – The Hall of Fame Voting Dilemma** A look at how Tyrer's personal tragedy affected his status as a finalist and the broader implications of the voting process.- **7:10 – Support from the Chiefs Organization** Kevin recounts how the Chiefs' historians and the old-guard players have offered unwavering support to Tyrer's family.- **14:15 – Behind the Documentary “Beneath the Shadow”** An exclusive preview of Kevin's upcoming documentary, including the emotional journey of the Tyrer family and the complex research behind the film.- **16:30 – Impact on Tyrer's Children** A heartfelt discussion about the traumatic experience for Tyrer's children and the resilience they've shown in the aftermath.- **20:30 – Family Resilience & Grandparents' Support** Insights into the remarkable role that grandparents played in helping the children cope with their loss.- **21:20 – Documentary Release & Voter Insights** Kevin reveals plans for the documentary's release, sharing how interviews with Hall of Fame voters provided crucial perspectives.- **24:20 – Debunking Myths & Voting Misconceptions** The duo examines how misinformation around the Hall of Fame process has muddied the waters when assessing Tyrer's legacy.- **26:10 – Cognitive Impairment & Moral Reasoning** A deep dive into how CTE impacts decision-making and behavior, challenging our conventional notions of premeditation.- **28:00 – Reflecting on Football History & Legacy** Kirk and Kevin discuss the enduring debate over how best to honor football legends amid complex personal histories.- **30:40 – Final Thoughts & What's Next** The conversation winds down with reflections on the future of Tyrer's narrative, upcoming projects, and a final word on the legacy of this storied figure.#JimTyrer #BuckStopsHere #NFLHistory #FootballLegacy #InvestigativeJournalism #KirkBuchner #KevinPatrickAllen #HallOfFame #CTE #DocumentaryIf Jim Tyrer's story resonates with you, please hit **like**, leave a comment sharing your thoughts, and subscribe for more in-depth discussions on football's untold stories. Let's keep the conversation going as we honor the legacies that shape the game!

Dr. William Horan (Bristol Myers Squibb) joins AJP Audio to discuss a newly approved, novel treatment for schizophrenia spectrum disorder, which has potential impacts for cognition in patients.  Afterwards, AJP Editor-in-Chief Dr. Ned Kalin puts the rest of the March issue into context. 00:45     Horan interview 03:15     Novel mechanism of action in the treatment of schizophrenia 05:39     Side effect profiles 07:20     Clinical impacts 08:31     The need for further investigation 09:58     Limitations 11:05     Further research 13:08     Kalin interview 13:21     Horan et al. 17:34     Levenstein et al. 19:00     Fountoulakis et al. 20:57     Couture et al. 23:18     Stern et al. 27:35     McGirr et al. Transcript Be sure to let your colleagues know about the podcast, and please rate and review it on Apple Podcasts, Google Podcasts, Spotify, or wherever you listen to it. Subscribe to the podcast here. Listen to other podcasts produced by the American Psychiatric Association. Browse articles online. How authors may submit their work. Follow the journals of APA Publishing on Twitter. E-mail us at ajp@psych.org

Taxpayers dollars went to doxxing opponents of pesticides, GMOs; Strontium for fracture healing? Vitamin D helps thyroid; Study highlights harmful effects of ultra-processed foods on cognition; Brain function needn't decline with age, may improve

In this episode of Science Matters, Reed and Dr. Aron Gonshor delve into the latest research on the gut microbiome, mild cognitive impairment, and the impact of probiotics. They discuss a recent double-blind, placebo-controlled study that highlights the significant role of gut bacteria in cognitive function among middle-aged and older adults. Additionally, Dr. Gonshor revisits topics from previous episodes, including RNA therapeutics and CRISPR technology, underscoring their potential to revolutionize medical treatments. Listeners are encouraged to engage with the show by submitting questions and suggested topics as the space of scientific discovery continues to grow. Join FDN and the team at the BiohackerExpo in beautiful Miami, Florida! Go to BiohackerExpo.com and use code "HDP" at checkout to get 50% off your tickets. Want to learn more about becoming an FDN? Go to fdntraining.com/resources to get our best free workshops and mini-courses!

This comprehensive program will explore schizophrenia's cognitive challenges with Dr Jose Rubio. Learn actionable steps to enhance patient care and outcomes. Credit available for this activity expires: 12/24/25 Earn Credit / Learning Objectives & Disclosures: https://www.medscape.org/viewarticle/unlocking-minds-navigating-labyrinth-cognitive-impairment-2024a1000p2v?ecd=bdc_podcast_libsyn_mscpedu

Vascular cognitive impairment is a common and often underrecognized contributor to cognitive impairment in older individuals, with heterogeneous etiologies requiring individualized treatment strategies.  In this episode, Katie Grouse, MD, FAAN speaks with Lisa C. Silbert, MD, MCR, FAAN, an author of the article “Vascular Cognitive Impairment,” in the Continuum December 2024 Dementia issue. Dr. Grouse is a Continuum® Audio interviewer and a clinical assistant professor at the University of California San Francisco in San Francisco, California. Dr. Silbert is is co-director at Oregon Alzheimer's Disease Research Center, a Gibbs Family Endowed professor of neurology, a professor of neurology at Oregon Health & Science University, a staff neurologist, director of Cognitive Care Clinic, and director of the Geriatric Neurology Fellowship Program at Portland Veterans Affairs Health Care System in Portland, Oregon. Additional Resources Read the article: Vascular Cognitive Impairment Subscribe to Continuum: shop.lww.com/Continuum Earn CME (available only to AAN members): continpub.com/AudioCME Continuum® Aloud (verbatim audio-book style recordings of articles available only to Continuum® subscribers): continpub.com/Aloud More about the American Academy of Neurology: aan.com Social Media facebook.com/continuumcme @ContinuumAAN Full transcript available here Dr Jones: This is Dr Lyell Jones, Editor-in-Chief of Continuum, the premier topic-based neurology clinical review and CME journal from the American Academy of Neurology. Thank you for joining us on Continuum Audio, which features conversations with Continuum's guest editors and authors who are the leading experts in their fields. Subscribers to the Continuum Journal can read the full article or listen to verbatim recordings of the article and have access to exclusive interviews not featured on the podcast. Please visit the link in the episode notes for more information on the article, subscribing to the journal, and how to get CME. Dr Grouse: This is Dr Katie Grouse. Today I'm interviewing Dr Lisa Silbert about her article on vascular cognitive impairment, which is part of the December 2024 Continuum issue on dementia. Welcome to the podcast and please introduce yourself to our audience.  Dr Silbert: Hi Katie. Thanks for having me here today. Like you mentioned, my name is Lisa Silbert. I am a behavioral neurologist at Oregon Health and Science University and my research focus is in the area of vascular contributions to cognitive impairment and dementia. Dr Grouse: It's such a pleasure to have you and I really enjoyed reading your article. Just incredibly relevant, I think, to most practicing general neurologists, and really to any subspecialty. I'd like to start by asking, what do you think is the main takeaway point of your article for our listeners?  Dr Silbert: Yeah. I think, you know, the field of vascular cognitive impairment has changed and evolved over the last several decades. And I would say the main take-home message is that vascular cognitive impairment or vascular dementia is no longer a diagnosis that is only considered in someone who's had acute decline following a clinical stroke. That we have to expand our awareness of vascular contributions to cognitive impairment and consider other forms of the disease that can cause a more subacute or slowly progressive form of cognitive impairment. And there are many, many forms of vascular cognitive impairment that present in a more slowly progressive manner. The other thing I would say as a major take-home message is that we know that cerebrovascular disease is a very common copathology with other forms of dementia and that it lowers one 's threshold for manifesting cognitive impairment in the context of multiple pathologies. And so, in this way, vascular cognitive impairment should be considered as a contributing and potentially modifiable factor in any dementia.  Dr Grouse: I found that last point just really, really fascinating. And also, you know, the reminder that a combination of pathologies are more common than any one. To your initial point, I'm actually curious, could you kind of outline for us how you approach diagnosing vascular cognitive impairment?  Dr Silbert: Yeah. So with everything in neurology, a lot of it comes down to the initial history taking. And so part of the work up always includes a very detailed history of the presentation of cognitive impairment. Any time there is an acute change in cognition, vascular contribution should be considered, particularly if it's in the context of a clinical stroke or some kind of event that might have lowered cerebral blood flow to the brain. And then having said that, I already mentioned there are many forms of vascular cognitive impairment that can mimic neurodegenerative disease in terms of its course. So being more slowly progressive. And so because of that neuroimaging, and in particular MRI, has become an extremely valuable tool in the workup of anyone who presents with cognitive impairment in order to evaluate contributions from cerebral vascular disease. And so, MRI is a really helpful tool when it comes to teasing out what may be contributing to a patient's clinical syndrome, as well as their other comorbid medical issues, including stroke risk factors and other kind of medical conditions that might contribute to reduce cerebral blood flow. Dr Grouse: I'd love to talk a little bit more about that. You know, as is often the case with neurologic disease associated with vascular pathology, the importance of prevention, you know, focusing on prevention of vascular diseases is so important. What are some things that we can make sure to focus on with our patients and, you know, particularly anything new to be aware of in counseling them? Dr Silbert: Yeah, I'm really glad you asked me that question because like I mentioned, you know, cerebral vascular disease is so common, it lowers one's threshold for cognitive impairment in the face of other age-related brain pathologies. And so, it's really important for all of us to focus on preserving our cognitive health, even starting in midlife. And so, there are a number of areas that I counsel my patients on when it comes to preserving cerebral health and maximizing cerebrovascular health. And so, these stem from the American Heart Association's Life's Essential 8 because we know that preserving cardiovascular health is likely going to also preserve cerebral vascular health. And so, some of the things that I'm very commonly discussing with my patients are controlling stroke risk factors such as blood pressure, blood sugars and cholesterol, maintaining a healthy weight, and then also working towards a lifestyle that includes a healthy diet, no smoking, regular exercise. And then new within the last couple years is also the recommendation that people get adequate sleep, which is something that hasn't been focused on previously. Dr Grouse: I was really interested in reading your article to learn about enlarged perivascular spaces and the role as a mediating factor in the interaction between through a vascular dysfunction and development and progression of neurodegenerative pathology. Can you elaborate on this further? Dr Silbert: So, this is an area that's still largely unknown in the field, and it's an area where there's a lot of emerging work being done. The short answer is, we really don't know with great certainty how it directly connects with accumulating Alzheimer's pathology. But there is some evidence to suggest that the perivascular space is involved in the clearance of toxic solutes from the brain, including Alzheimer's disease pathology. And so there's a lot of work looking at how potentially cerebrovascular risk factors might affect the clearance of those toxic solutes through the perivascular space, including pulse pressure changes that might occur with accumulating cerebrovascular disease and other potential contributors. But one thing I can say with more certainty is that the, you know, location of perivascular spaces is thought to help distinguish those who might have cognitive symptoms due to cerebrovascular disease versus due to cerebral amyloid angiopathy. Or I guess I should say location is helpful in terms of recognizing vascular contributions to cognitive impairment that's due to arteriolosclerosis versus that due to cerebral amyloid angiopathy. In so much that… when we see a lot of perivascular spaces in the basal ganglia in the subcortical structures, that is thought to be more associated with arteriolosclerosis and hypertension type related vascular cognitive impairment. Whereas when we see multiple perivascular spaces within the centrum semiovale, that tends to be more associated with cerebral amyloid angiopathy. Dr Grouse: That's so interesting. And on the topic ofcerebral amyloid angiopathy, you did go into this a good deal. And you know, I think I encourage everybody to revisit the article to remind themselves about, you know, the findings that can increase the suspicion of tribal amyloid angiopathy. However, you also talked about transient focal neurologic episodes, which I think is just a great reminder that, you know, these can occur in this setting and definitely not to miss. Tell us more about what to look for with these types of episodes.  Dr Silbert: Transit focal neurologic episodes can be very difficult to tease apart from a transient ischemic attack. And these transient focal neurologic episodes due to CAA can present in a number of different ways. And I think the important take home message for that is that in people who have neuroimaging evidence of CAA to inform them that they are at increased risk for having these focal neurologic episodes and that if they do present to a hospital or an emergency department with any kind of neurologic event, that those treating them are aware that they have evidence of CAA on their neuroimaging because the treatment of course is quite different. So, it's someone presenting with ATIA who has transient neurologic symptoms might be considered urgently to get a thrombolytic or, you know, TPA, whereas someone who has known cerebral amyloid angiopathy or suspected CAA, they likely already have microbleeds on their neuroimaging and in those cases thrombolytics and TPA would be contraindicated and not helpful in terms of the etiology of their neurologic symptoms. Dr Grouse: That's a really good point to make. And I think also in your article you mentioned the use of aspirin if you're suspecting ATIA versus a, you know, a transient amyloid related focal neurologic episode. You know, one you would treat with aspirin and the other one you wouldn't.  Dr Silbert: That's right.  Dr Grouse: Another sort of interesting topic you delved into was cerebral microinfarct and how this can also contribute to vascular impairment. Could you elaborate a little more on that? Dr Silbert: Yeah. So cerebral microinfarcts are kind of the hidden cause of or a hidden cause of vascular cognitive impairment. And it's extremely challenging because by definition they are not visible on routine clinical neuroimaging. It's something that we are more aware of based on pathological studies and neuroimaging studies that have been done at ultra-high field strength like 7T MRI. And so, we are just learning more about how prevalent they are in certain conditions and how we can only look at these after death when we're looking at brain tissue and then go back and realize that these play a significant role in cognitive decline when someone is alive. It's important to understand that we're probably only appreciating kind of the tip of the iceberg when we're evaluating a patient and looking at their neuroimaging. That what we're actually seeing on MRI are only the things that are actually quite relatively big and obvious. And that a lot of these neuroimaging features of vascular cognitive impairment are actually associated with pathologic features that we're missing such as microinfarcts. But the hope is that by treating all individuals, particularly those who already have signs of vascular cognitive impairment, by modulating their stroke risk factors and focusing on maintaining brain health, that those will, interventions will also reduce the incidence of microinfarcts. Dr Grouse: What do you think is the greatest inequity or disparity you see in treating patients with vascular cognitive impairment? Dr Silbert: I think the greatest disparity is- really starts way before I treat a patient. That relates to really focusing on healthy lifestyle factors early in life and being able to, you know, afford fruits and vegetables, and having the advantages of being able to exercise regularly, and just being aware that all of these things are extremely important before older age. So, these are things that, you know, I think more education and awareness and greater access to healthcare will definitely improve access to. Even preventative healthcare is a disparity and not available across all of the population and geographic locations. So, I think of the- all the dementias, vascular cognitive impairment probably has the greatest association with health and social disparities in terms of primary prevention and access to care.  Dr Grouse: All really important things to consider. I have to say when, you know, reading your article, dare I say I came away with a little bit of hope thinking, you know, even with, you know, how little we still, you know, or how much we still need to do to really learn how to fight Alzheimer's and, you know, prevent it and, and, you know, help with its progression. The idea that in so many cases, even just doing what we can to prevent the vascular or cognitive impairment can really help any type of dementia. That was really a strong message for me. Do you mind elaborating on that a little more?  Dr Silbert: No, not at all. I agree. I really am hopeful about the prevention and treatment of dementias and through the treatment and prevention of cerebrovascular disease. I think that is a true reality, just like, you know, as we were discussing before, the treatment and prevention of cerebrovascular disease really should be a part of the treatment of any type of cognitive impairment and recommendations for prevention of cognitive impairment. This is the, you know, one thing we know is largely modifiable and preventable in most cases. I think the, really the key thing is just education and making sure that people understand that these are things that really need to be, they need to be engaged in in midlife and that it's much harder to reverse these- the damages once you have them in later life. Having said that, I do think that there's greater awareness of maintaining healthy lifestyle and maintaining awareness of stroke risk factors. And I think we're already starting to see a reduction in dementia worldwide in several large population-based studies, and probably that is due to more attention to the modifying stroke risk factors. So, I agree with you, it's very encouraging.  Dr Grouse: Is there anything exciting on the horizon that you can tell us about that we should all be keeping our eyes out for? Dr Silbert: Yeah. So, you know, I'm really interested in this connection between vascular cognitive impairment and Alzheimer's disease. And it's a real area of exciting new research. And so I think we're going to have more answers as to how, whether and how, cerebrovascular disease is directly linked to accumulating neurodegenerative disease or neurodegenerative pathologies. The other area that's, I think, really exciting, that's moving forward, is the in the area of blood-based biomarkers for vascular cognitive impairment. As these emerge, we'll be able to really identify those at greatest risk for vascular cognitive impairment, but also identify novel mechanisms that lead to VCI that can be targeted for therapeutic intervention. Dr Grouse: Well, I'm really excited to see what's coming down the pipeline and what more we'll learn in this area. So, thank you so much for everything you've done to contribute to this field. Dr Silbert: Yeah.  Dr Grouse: I wanted to ask a little bit more about you. What drew you to this work?  Dr Silbert: Well, actually, so my very first published manuscript in medical school was a case report and review on MELAS, which is mitochondrial encephalopathy with lactic acidosis and strokelike syndrome. And so, I was really fortunate to have Dr Jose Biller, who is a renowned expert in stroke and cerebrovascular disorders, as my mentor for that paper. And so, that got me really interested in neuroimaging findings of cerebral vascular disease. And so when I was a fellow at Oregon Health and Science University, I was then really fortunate to  be able to work with Jeffrey Kaye's oldest old population. And in working with that population, I really became interested in their neuroimaging findings of these white matter lesions and just realizing how prevalent they were in that population, you know, it just led me to start investigating their clinical significance and etiology, which kind of led me along this path. Dr Grouse: You know, Lisa, thank you so much. I really learned a lot from your article, and I think our listeners will definitely find that it was very helpful for their practice. Thank you so much for joining us. Dr Silbert: Thank you so much, Katie. It's been really fun.  Dr Grouse: Again, today I've been interviewing Dr Lisa Silbert, whose article on vascular cognitive impairment appears in the most recent issue of Continuum on dementia. Be sure to check out Continuum audio episodes from this and other issues. And thank you to our listeners for joining today. Dr Monteith: This is Dr Teshamae Monteith, associate editor of Continuum Audio. If you've enjoyed this episode, you'll love the journal, which is full of in-depth and clinically relevant information important for neurology practitioners. Use this link in the episode notes to learn more and subscribe. AAN members, you can get CME for listening to this interview by completing the evaluation at continpub.com/AudioCME. Thank you for listening to Continuum Audio.

Giving Perspective on the Recent Report on Water Fluoridation and Cognitive Impairment By Spring Hatfield, RDH, BSPH Original article published on Today's RDH: https://www.todaysrdh.com/giving-perspective-on-the-recent-report-on-water-fluoridation-and-cognitive-impairment/ Need CE? Start earning CE credits today at ⁠⁠https://rdh.tv/ce⁠⁠  Get daily dental hygiene articles at ⁠⁠https://www.todaysrdh.com⁠⁠ Follow Today's RDH on Facebook: ⁠⁠https://www.facebook.com/TodaysRDH/⁠⁠ Follow Kara RDH on Facebook: ⁠⁠https://www.facebook.com/DentalHygieneKaraRDH/⁠⁠ Follow Kara RDH on Instagram: ⁠⁠https://www.instagram.com/kara_rdh/

#ThisMorning on #BRN #Wellness #1913 | Education, Occupation and Wealth Affect the Risk of Cognitive Impairment  |  Dorina Cadar, BSc, MSc, PgCert, PhD, Director of the Cognitive Epidemiology, Dementia, and Ageing Research lab, University of Sussex | #Tunein: broadcastretirementnetwork.com #Aging, #Finance, #Lifestyle, #Privacy, #Retirement, #Wellness and #More - #Everyday | #Subscribe with #DiscountCode ‘BRN20'

The brain's ability to recover after trauma is astonishing—and often overlooked in conventional care. In this episode of New Frontiers in Functional Medicine, I sit down with Dr. David Musnick, a long-time friend and brilliant clinician, to explore how we can unlock the brain's full potential for healing. Dr. Musnick challenges the standard of care for traumatic brain injuries and post-concussion syndrome, introducing a functional medicine approach that integrates advanced tools like Frequency-Specific Microcurrent, targeted nutritional strategies, and personalized interventions. His insights into the stages of recovery, the importance of addressing neuroinflammation, and the role of the gut-brain connection were a true "aha" for me. We also dive into groundbreaking methods for reversing secondary brain damage, a concept that could change everything for patients and practitioners alike. This conversation is packed with actionable takeaways and hope for those navigating brain injuries, cognitive impairment, or persistent post-concussion symptoms. You don't want to miss it.~DrKF Check out the show notes at https://www.drkarafitzgerald.com/fxmed-podcast for the full list of links and resources. GUEST DETAILS David Musnick MD FMI Center for Optimal Health http://www.fmioptimal.com http://www.peakmedicine.com Clinic: (208)609-9130 David Musnick MD is a Sports Medicine and Functional Medicine MD who practices in Eagle Idaho and Bellevue WA. In 2016 he developed the first program to heal the brain after Concussion based on the Pathophysiology mechanisms that go on after a Concussion and TBI. He has healed hundreds of patients and is published on his approach in the book Integrative Neurology. In his practice he defines the brain areas that have been injured and develops a detailed approach to healing these areas. His approach integrates food choices, supplements, sleep, exercise, EMF protection, HBOT and Frequency Specific Microcurrent. He has expanded his approach to also treat Cognitive Impairment and other Neurological disorders such as MS and Parkinson's. He sees patients in both Idaho and Washington but can see patients from other states on Telemedicine via a Peer to Peer consultation. THANK YOU TO OUR SPONSORS DIAMOND Precision Analytical: https://tinyurl.com/4anbz7b3 Biotics Research: https://www.bioticsresearch.com/ Integrative Therapeutics: https://tinyurl.com/4emwj48z GOLD OneSkin: https://tinyurl.com/ycxtw4zt TimeLine Nutrition:: https://tinyurl.com/bdzx2xms MIDROLL OneSkin: https://tinyurl.com/ycxtw4zt DUTCH https://dutchtest.com/ CONNECT WITH DrKF Want more? Join our newsletter here: https://www.drkarafitzgerald.com/newsletter/ Or take our pop quiz and test your BioAge! https://www.drkarafitzgerald.com/bioagequiz YouTube: https://tinyurl.com/hjpc8daz Instagram: https://www.instagram.com/drkarafitzgerald/ Facebook: https://www.facebook.com/DrKaraFitzgerald/ DrKF Clinic: Patient consults with DrKF physicians including Younger You Concierge: https://tinyurl.com/yx4fjhkb Younger You Group Program: https://tinyurl.com/4hvusavw Younger You book: https://tinyurl.com/mr4d9tym Better Broths and Healing Tonics book: https://tinyurl.com/3644mrfw

In this episode of the Crazy Wisdom Podcast, I, Stewart Alsop, sit down with Matt Omernick, a pioneer in leveraging interactive technology for health and cognitive improvement. We explore his journey from traditional game development to creating transformative digital therapeutics, touching on how technology like video games and AI is reshaping cognitive health, creativity, and human potential. Matt also shares his insights into the FDA approval process for these groundbreaking tools, discusses the role of creativity in a tech-driven future, and highlights the importance of ethical AI practices. For those interested in Matt's work, you can connect with him on LinkedIn to dive deeper into his ongoing projects.Check out this GPT we trained on the conversation!Timestamps00:00 Introduction and Guest Welcome00:29 Neuralink and Cognitive Impairment01:20 The Cognitive Crisis and Technology's Role03:18 Digital Therapeutics and AI Biometrics03:44 AI Augmentation and Creativity05:33 The Future of AI and Creativity08:02 Closed Loop Systems and Personalized Technology11:42 Generative AI and Ethical Considerations16:20 Art, Suffering, and Creativity19:30 The Human Element in AI20:10 Adaptability: Humanity's Strength and Weakness22:05 The Role of AI in Creative Fields23:08 Fragmentation and Tribalism in the Age of AI24:46 Evolutionary Biology and Human Adaptation28:14 Digital Health and Therapeutics30:33 Navigating the FDA Approval Process35:46 The Future of AI in Bureaucracy39:37 Conclusion and Contact InformationKey InsightsTechnology as a Tool for Cognitive Health: Matt Omernick highlights the transformative potential of interactive technologies like video games in addressing cognitive impairments. Once stigmatized, video games are now proving to be powerful tools in promoting mental health, supported by rigorous scientific evidence. These innovations open a new frontier in digital therapeutics, making it possible to create adaptive experiences that train the brain and yield measurable, durable improvements in cognitive function.The Role of AI in Creativity and Problem-Solving: AI is reshaping creativity by serving as an augmentation tool rather than a replacement for human ingenuity. Matt draws parallels to the introduction of tools like Photoshop, emphasizing that AI enables artists and creatives to work faster, experiment more, and push boundaries, while still relying on human input to guide its applications. This partnership between humans and AI is a significant shift, particularly in industries like gaming and digital art.The Cognitive Crisis of Overstimulation: Modern society faces a cognitive crisis driven by unprecedented levels of stimulation from technology. Matt discusses how primitive brain structures are struggling to cope with the demands of a hyper-connected world. However, instead of retreating from technology, he advocates leveraging it intelligently to create systems that help humans adapt and thrive in this new environment.FDA Approval as a Milestone for Digital Therapeutics: Achieving FDA approval for a video game-based therapeutic was a groundbreaking step, validating the legitimacy of this new form of medicine. The process involved creating a new regulatory framework tailored to digital products, blending the rigor of traditional clinical trials with the flexibility of software development. This achievement paves the way for future innovations in digital health.The Power of Closed-Loop Feedback Systems: Closed-loop systems, which continuously measure and adapt based on user input, are central to the success of digital therapeutics and other adaptive technologies. Matt explains how this approach not only optimizes cognitive training but also offers a model for creating highly personalized and effective interventions in health and wellness.Ethics and Responsibility in AI Development: Matt underscores the critical need for ethical practices in AI, particularly in creative fields. Protecting artists' rights, ensuring transparency in how AI is trained, and addressing potential biases are essential for fostering a future where technology serves humanity's best interests without exploitation or harm.A Hopeful Vision for the Future: Despite potential dystopian outcomes, Matt remains optimistic about the trajectory of technology. He believes humanity's adaptability and creativity will guide us toward solutions that enhance our lives and address major challenges. His work exemplifies this optimism, focusing on creating tools that blend technological sophistication with ethical and human-centered design principles.

Monica Le Baron, an MBA, best-selling author, and sleep expert, specializes in helping ambitious women with sleep disorders achieve a good night's rest in 30 days or less through her program, Sleep Simplified. Her expertise has been recognized by the International Association of Yoga Therapists, Healthy Women, Telemundo 48, and the Insight Timer app. With her proven approach, clients have successfully attained 8 hours of restful sleep, reduced nighttime awakenings, and accelerated sleep initiation. Leveraging her own experience in overcoming insomnia, chronic pain, stress, and anxiety, Monica's commitment to improving sleep quality positions her as a valuable resource for individuals seeking to optimize their well-being.   The key moments in this episode are:   00:02:05 - Monica's Journey to Becoming a Sleep Coach  00:08:09 - The Four-Step Framework for Better Sleep  00:11:06 - Finding Your Optimal Sleep Time  00:14:45 - Structural Abnormalities and Sleep Support  00:17:24 - Cognitive Impairment from Lack of Sleep  00:20:34 - Importance of Quality Sleep  00:21:53 - Addressing Sleep Gap and Shift Work   Connect with Monica Le Baron Website: monicalebaron.com LinkedIn: linkedin.com/in/monicalebaron Facebook: facebook.com/sleepsimplified Instagram: @monica.le.baron   Connect with Amina AlTai Website: aminaaltai.com Instagram: @aminaaltai TikTok: @theaminaaltai Linkedin: linkedin/in/aminaaltai

In a cross-sectional analysis from the CONSTANCES cohort study, hearing loss in middle-aged French adults was linked to increased odds of cognitive impairment. Although hearing aid use did not significantly lower the odds of cognitive decline overall, it did show benefits for those with depression. The World Health Organization recommends vaccinating pregnant women in their third trimester to protect newborns against RSV, though global access to vaccines like Pfizer's Abrysvo remains limited. Finally, University of Michigan researchers developed a microchip that rapidly detects cancer-specific exosomes in blood, potentially enhancing early lung cancer diagnosis.

The post 308: Cognitive Impairment, Anticipated Regret, Eating Speed and Her New Book With Emily Troscianko appeared first on Seven Health: Eating Disorder Recovery and Anti Diet Nutritionist.

Today, I give you the research on diet and lifestyle therapy that is proving to help people live longer- better. I really should have a drum roll here but the research is showing that 71-90% of people with cognitive decline, some with diagnosed Alzheimer's disease get better.

Host Dr. Davide Soldato and Dr. Shelia Garland discuss the JCO article "Randomized Controlled Trial of Virtually Delivered Cognitive Behavioral Therapy for Insomnia to Address Perceived Cancer-Related Cognitive Impairment in Cancer Survivors." TRANSCRIPT The guest on this podcast episode has no disclosures to declare. Dr. Davide Soldato: Hello and welcome to JCO After Hours, the podcast where we sit down with authors from some of the latest articles published in the Journal of Clinical Oncology. I am your host, Dr. Davide Soldato. I am a Medical Oncologist at Ospedale San Martino in Genoa, Italy. Today we are joined by JCO author Dr. Sheila Garland. She's a Professor of Psychology and Oncology at Memorial University, and she's the director at the Sleep, Health, and Wellness Lab and Senior Scientist at the Beatrice Hunter Cancer Research Institute. Dr. Garland will be discussing the article titled, “Randomized Controlled Trial of Virtually Delivered Cognitive Behavioral Therapy for Insomnia to Address Perceived Cancer-Related Cognitive Impairment in Cancer Survivors.” Thank you for speaking with us, Dr. Garland.  Dr. Sheila Garland: Thank you so much for having me. Dr. Davide Soldato: So, Dr. Garland, you designed a study that relied on cognitive behavioral therapy to treat insomnia, and then you assessed whether improvement in insomnia would be associated with an improvement in cancer related cognitive impairment. So I wanted to ask if you could give us a little bit of context and explain the rationale between these studies. So how common are these symptoms among cancer survivors, and why do we think that improving insomnia would also improve cognitive function?  Dr. Sheila Garland: Yeah, thank you very much. That's a really, really good question. And so cognitive behavior therapy for insomnia has been used to successfully treat insomnia in cancer survivors for quite some time. I think JCO was one of the first publishers to really demonstrate the potency of this intervention to improve insomnia. But as we know, patients will often present not just with insomnia, but insomnia comorbid with pain, fatigue, and very commonly cognitive impairment. If we take a look at the experimental research in sleep, we know that sleep quality and quantity is associated with very important cognitive functions. And so we've had clear sleep deprivation studies where if you're not able to successfully get sufficient quality or quantity of sleep, you're going to have impairments in attention and concentration and memory. So it really makes sense that if we're able to improve sleep in cancer survivors, that we're also able to address maybe some of the other concerns that they would have related to sleep. So this is an important clinical question for the patient's quality of life, but I also think it has important system implications where if we're looking at like resources and efficiency of allocating those resources, if we have an intervention that can treat multiple problems, that means that we can more effectively address lots of symptoms and use fewer resources in doing so. So that was the thought in designing this trial. Dr. Davide Soldato: Thank you very much. That was very, very clear. So you spoke about the intervention that you implemented in the clinical trial. So I was wondering if you could give us a little bit of context. How long was the intervention? What were the main points addressed? Because you said that, in the end, we already have some data regarding cognitive behavioral therapy for treating insomnia. So I was wondering, did you personalize in any way, the program or the intervention to fit more to the cancer survivors population?  Dr. Sheila Garland: Yeah. So it is based on a protocol that has been well researched and has a great deal of evidence of efficacy. But we delivered this intervention over a course of seven weeks. So individuals had individual sessions with a trained therapist, and those sessions lasted about an hour and were over roughly about two months or so. Seven sessions over two months. And because they were delivered individually, there was some adaptation based on the clients' presenting problems. So while there's sort of a standard protocol, if the client is also presented with levels of fatigue or pain or anxiety or depression, the therapist was able to integrate those concepts into the therapy as well. There was nothing for cognitive impairment. So there was no additional intervention for cognitive impairment at all. We weren't doing any memory training or anything like that. So it was strictly the sleep and other symptoms looking at the impact of improving that on not only your perception of your cognitive abilities, but also on performance on a number of neuropsychological test measures. Dr. Davide Soldato: So thank you very much for the detail. And I think that it's very interesting what you said, that the personalization of the intervention would also allow to treat some other symptoms that are distressing for cancer survivors. Like, for example, you mentioned fatigue or anxiety or depression. And I think that this goes back to the first point that you made about the intervention. So being able to treat different symptoms all at one in one single intervention, I think that that is a very intelligent use of resources and also to promote and implement, potentially some interventions that are beneficial for survivors of cancer on different domains and potentially different symptoms. So, going to the results a little bit, what did you observe regarding specifically insomnia with the intervention that you delivered? Dr. Sheila Garland: Yeah, so, of course, we wanted to make sure that we were effective in targeting the primary outcome of what the trial was supposed to do, which was we were supposed to treat effectively, treat insomnia, and then determine whether treating that insomnia was related to improvements in cognition. So we were expecting that the intervention itself was going to be successful at improving insomnia, and we were. So we were able to not only demonstrate a statistically, but also a clinically meaningful improvement in insomnia severity. Usually that's measured by a change of about 8.4 on a measure called the insomnia severity index. And the change that we were able to produce was over 11 points. So it was clearly over the clinically meaningful change threshold. Dr. Davide Soldato: Going back a little bit to the design of the study, this was a randomized clinical trial. And how did you allocate the participants of the study into which arms? And can you guide us a little bit in the study design?  Dr. Sheila Garland: Yes. A lot of thought went into the study design. We ultimately decided on having a waitlist randomized controlled trial, and this was because there is no other intervention for insomnia that has comparable efficacy. And we felt it would be unethical to not give people the standard treatment that we know works to treat insomnia. So that's where having them wait for a period of time and then receive the treatment was ultimately what we decided on. Overall, we were able to recruit 132 participants, and those were randomized into either receiving treatment immediately or receiving treatment after a two month waiting period. Dr. Davide Soldato: So you mentioned that the intervention was actually very effective for treating insomnia. You reported an improvement in the insomnia severity index of almost 11 points. And as you mentioned, this is both clinically meaningful and it was also statistically significant. Did you see any improvement also on cognitive function, and how did you measure this outcome? Was it self reported, or did you also have some objective measure to see, for example, working memory or some other type of cognitive function? Dr. Sheila Garland: Yeah. Also, a lot of thought went into choosing the primary outcome for this. And there's people who have argued compellingly that self reported cognitive function should be the primary target because we know, based on past research, that objective and subjective ratings of cognitive performance do not always correlate well with each other. And taking a very patient oriented approach, we wanted to make sure that we prioritized the patient's perception of their own function. We used one of the subscales of the functional assessment of cancer treatment cognition scale. So it was the Perceived Cognitive Impairment subscale that was what we used as our primary, but we also reported the two other subscales, which was the Perceived Cognitive Abilities and the Impact of Cognition on Quality of Life. We were able to not only discover that there were clinically significant improvements on all three of those subscales, but actually translated into, again, the clinically meaningful change threshold that's been established for the perceived cognitive impairment subscale is, I think it's around, like 5.9 points. So, using that cutoff, 75% of the participants in the trial reported clinically meaningful improvements in their perceived cognitive impairments, compared to just 43% of those participants in the wait list group. And we looked not only at the immediate intervention effects, but also on whether they were durable. So we had follow up assessments of both three months and six months after completing treatment, and the effects on insomnia, as well as the cognitive dimensions, they were maintained.  Dr. Davide Soldato: Thank you very much for this last remark, because I think that one of the worries I would say that we have when implementing this type of behavioral intervention is that in the end, the change that we produce and the behavioral change that we produce might be effective in the immediate time after completing the intervention. But frequently we sort of see the loss of this benefit that we produce with the intervention at later time points. And I think that this is very important that you also looked at the benefit that was maintained over time for the three and six months after the end of the intervention. And it's true that before we add some data regarding other types of behavioral intervention, for example, for weight loss or some other symptoms and other toxicity that we frequently target with this type of intervention, I was wondering, do you think that it's something specific to cognitive behavioral therapy and the specific symptoms that you were treating, so insomnia, that in the end, produced a durable and meaningful benefit over time?  Dr. Sheila Garland: So I do think that there's something really specific about this type of intervention. With insomnia, you're really changing the person's fear of not sleeping, and you're giving them tools to be able to both prevent the reocurrence of insomnia and also if the reocurrence should happen, they know what to do then to address it themselves. I was very curious about the impact that it might have long term. I actually wasn't sure whether it would have an effect immediately, considering that people do accumulate kind of a sleep debt after having insufficient sleep for a period of time. So I didn't know whether we would see anything immediately. I thought maybe we would need the long term follow ups to see some of the effect. But I guess maybe not surprisingly, at the end of the trial, thinking about when somebody has a good night's sleep, they're feeling the effects even the next day. Dr. Davide Soldato: Thank you. That was very insightful. Regarding the duration of the intervention, because in the end, this was very short, because it was just seven sessions weekly, and usually also when we design or implement this kind of behavioral intervention, we frequently go for a longer period of time where the patient is subjected to this type of behavioral intervention. Frequently, we see around three, six months of intervention. And so I think it's really amazing the effect that you had on this specific symptom with such a short intervention. So I think that that is also something that speaks to the possibility of further implementing this type of intervention and this type of program for symptom control.   And going back a little bit to what was one of the main questions of the trial that you designed and the results of the article that you published, did you observe a mediating effect of the improvement of insomnia on the cognitive function? So, you said that insomnia improved, and so improved also your primary outcome, which was the scale of the FACT-Cog questionnaire. But did you see whether this improvement in cognitive function was really related and associated to the improvement that you observed in insomnia? Dr. Sheila Garland: Yeah. So that was a very, very important question. We needed to first demonstrate that there was a relationship between the intervention and insomnia, and then there was a relationship between insomnia and cognition. And then we did some mediation analyses subsequent to determining both of those, and we found that the change in insomnia was a full mediator of the change in cognition. So we were able to say that it's not just time or it wasn't related to something else, that improving sleep did have this direct effect on the improvement that patients reported in their cognitive impairment.  Dr. Davide Soldato: We spoke a lot about the subjective improvement in cognitive performance. But you said that you also evaluated some specific and objective scale with, for example, I imagine some neuropsychological tests. Did you also observe some improvement for those specific tests, and did you observe the same amount of benefit or the same improvement, we could say, between the subjective and the objective weight of measuring cognitive function?  Dr. Sheila Garland: I think that's where the outcomes become a little less clear. So, we did measure performance based cognition at all of the time points, and we were very careful in selecting these measures. So we followed the guidance provided by the International Task Force on Cognition and Cancer. They had some very specific recommendations about how and what measures we use. So we made sure to use measures that were able to be repeated, so that had multiple forms, that had very identifiable ways to indicate improvements. So we used the Hopkins Verbal Learning Test to measure word recall, both immediately and delayed. We used measures to look at verbal fluency and working memory. Overall, we had six different specific aspects of cognition that we were looking at, immediate word recall, delayed word recall, word retention, verbal fluency, word recognition, and working memory. Some of those presented with a different pattern of change overall. So a little bit trickier to interpret than the person's perception of their own cognition. Dr. Davide Soldato: That's very interesting because it's important to have this kind of objective assessment. But in the end, what we are really trying to target is a symptom that is distressing for cancer survivors. I'm not even sure that sometimes we need all of this detail, or at least that even if these outcomes that are more objectively measured, we do not observe the same amount of benefits. Still, if we are able to produce an improvement in the symptoms and the perception that the survivor or the individual or the patient, whoever we are trying to help in that specific moment and for those specific symptoms, reports an improvement, I think that is already very important. And I totally share the patient oriented approach that you followed in the study.  Going back a little bit to the population, because I think that this speaks a little bit also to potential avenues for further research. You included a population of cancer survivors who completed treatment at least six months before being enrolled in the trial. And relating to the population, I had two questions. So the first one is, do you think that you would have the same kind of results, so the same benefit, also among a population of patients who's in active treatment? And then the second one is a little bit more speculation, but do you think that we will arrive, or do you envision research where we kind of deliver this type of intervention in sort of a preventative way? So if we would be able to identify those patients who might later develop these types of symptoms, could we use this type of intervention sooner? So can we prevent these symptoms even before they appear? And could this be potentially associated also in a less symptoms developed over time and less need to treat these symptoms when they become more severe?  Dr. Sheila Garland: Those are two very, very good questions. The first one is regarding the population. You're right. These people were at least six months out of treatment, and we wanted to make sure that if there was any temporary disruption, that would have maybe been stabilized over that. But most of the people in this trial, and I will mention that we didn't focus on any specific cancer type or site. So this was really a heterogeneous group of cancer survivors, both male and female. The most prevalent diagnosis that we had was breast. But some of these people who were enrolled in the trial had advanced cancer, and as long as their cancer treatment, their regimen was stable, they were eligible to participate in the trial. So I think that's a very important point. If somebody is on a very intensive round of chemotherapy, it can be tricky to implement some of the more aggressive behavioral changes that can come with some of these insomnia treatments, because their level of wellness just isn't there. So during active treatment it can be challenging, but it is definitely not impossible. We would just tweak things a little bit to accommodate their physical well being at that time.  To your next question, though, this is where I think we really need to be going. Just like they've done in the area of, like, physical activity, trying to really strengthen people prior to treatment is the way to go. Because some of my other research looked at symptoms prospectively from the time of diagnosis over the first year, and it's roughly about half of people, at least, this was in my work with women with breast cancer, about half of women with breast cancer come into treatment with clinically significant sleep problems. So, a proportion of those people just continue to have sleep problems or even get worse after it. So there's definitely a role for that, sort of like rehabilitation, not only for maybe physical fitness to try and ward off fatigue, but also getting their sleep on track. I think people are really focused, especially in that early time, about like, “I want to eat right, I want to exercise,” but I say it as many times as I possibly can, that you're not going to make healthy food choices, and you're not going to be getting out there and working out if you're not getting sufficient sleep. So we really need to have sleep there as the foundation and what supports all of those other healthy lifestyle behaviors that people are trying to change. Dr. Davide Soldato: So sort of comprehensive intervention for people undergoing treatment where we kind of identify symptoms that are already there at the beginning, and we deliver some sort of intervention that can target a lot of those symptoms, maybe not all of them, but maybe improving also the way that treatment is perceived or the toxicity that they might develop over treatment. Dr. Sheila Garland: And that's what I think. I think that if you're taking people who are already coming into treatment, that are looking after their health in ways that they can, they may be able to tolerate more aggressive treatments, they might be able to complete more rounds of chemotherapy, just getting them strong, going into treatment that way.  Dr. Davide Soldato: Also still focusing on that very patient oriented perspective that I think it's very important in general for oncologists and also for patients. I think that you were very wise in choosing an intervention that could be also delivered virtually, and this was one of the bases of the intervention. And regarding also the way the intervention was delivered, I had a question regarding the fact that this was actually an intervention that was delivered by professionals. But we also have some, maybe initial evidence, that suggests that some of this cognitive behavioral therapy can also be experienced, or at least the benefits can be obtained by the patients, even when it's self directed. So programs where patients are not actually interacting with a professional, but they are just following these types of programs. So do you think that there is room for both of those? And maybe should we suggest this type of self directed programs for all patients or all survivors and then just refer only those with a more significant or important symptom severity for the intervention with professionals? And this, I think, also goes to the discussion that we had at the very beginning about allocation of resources and ability also to tailor these types of interventions to the needs of different individuals. Dr. Sheila Garland: I think that's really important to consider when looking at what's available for patients. They did a survey in the US of NCI Cancer Centers where they looked at the availability of CBT-I, and it was very low. I think around 20% or so of NCI Comprehensive Cancer Centers had the ability to refer to in-house CBT-I. If we had sort of a stepped care model like you're talking about, we may be able to more appropriately allocate people to the level of care that they need. A line of my research now is going into a specific app delivered cognitive behavior therapy for insomnia tailored to cancer survivors. And so looking at that very point, not everybody needs a provider, but I think that a self help manual or an app is also not going to work for everybody. So you're not going to completely take out the person. And depending on the complexity of the situation that the patient finds themselves in, they may really need that provider to consider all of the other factors. They might need it to encourage adherence or address maybe some of the barriers that would be getting in the way. So having different levels of care and being able to match people not only to the level of care, but also maybe by their preference. So, “I'd like to use an app.” Great, we've got an app for you. Or “I'd like to see somebody.” And I think matching it to people's preferences automatically encourages or enhances their engagement and their motivation to complete because they're getting what their preference would be. Dr. Davide Soldato: And I think that at least if we could use a little bit more of these types of apps or tools or whatever we have out there, maybe we could increase at least that 20%. For example, if only 20% of NCI Cancer Centers, which are already places where care is delivered, probably with a higher attention to these types of symptoms for survivors compared, for example, to community hospitals or to smaller private clinics. So if we could at least have sort of a base and then refer only those that maybe have a higher need for a provider directed therapy or intervention, that maybe would also improve outcomes for a larger part of the population of survivors.   And one other thing that I wanted to ask you is, do you think, in your experience, because this was not really in the trial that you designed, but do you think that we also need cultural adaptation of these types of programs? Meaning, do we need to diversify based, for example, on ethnicity or level of education or, I don't know, just the background that the patient is experiencing? Dr. Sheila Garland: Yeah, very, very good points. There are some studies currently being conducted out of the United States that have looked at cultural adaptations of CBT-I specifically. So there was a trial looking at CBT-I for African American women survivors of breast cancer, and also the Latinx population as well. From the results of those trials, it didn't necessarily improve the effects of intervention, but it improved the engagement, so people were less likely to drop out. So it wasn't always the content. It was how the content was presented. So people were able to visually see themselves more, they were able to relate more to the content in just the way it was presented, which made them go, “Oh, okay. This is why I should be here.” And I think that that's part of the argument that I used for sort of adapting the cognitive behavior therapy for insomnia treatment that's being used in the general population, specifically to people who have had cancer, because people want to know, “All right. You know what? Is this safe for me to do? Will this work for me to do? How do I also do this when I have cancer related fatigue, or how do I do this when I also have pain?” So they want to know that, “Alright. This is right for me.” That's probably, again, relating more to getting people and keeping people engaged with the treatment, maybe even convincing them to do it to begin with, talking about getting buy-in from important leaders in their community to say, “This is something that I would recommend or I would endorse.” And those sort of community level endorsements maybe are just breaking down barriers to get people willing to engage with an evidence based treatment.  Dr. Davide Soldato: And I think especially with cognitive behavioral therapy, because I think that when we propose drugs for treating symptoms or, I don't know, intervention for losing weight or to be more physically engaged, well, the latter that I mentioned might be also a little bit more complicated, depending on the cultural context. But drugs are very easy to accept for the patients in most cases. But I think that cognitive behavioral therapy also has some type of cultural resistance, maybe among some of our patients and cancer survivors.  Dr. Sheila Garland: And I would also include oncologists in there as well. So, some of the treatment providers are not even exactly sure why would talking about this help. So I think separating it out, it's not just I'm going to talk about my sleep, it's that I'm going to engage with my sleep differently and breaking down maybe some of the stigma that, just because we're referring you to cognitive behavior therapy doesn't mean your problems are all in your head, but it means that there's ways that you can think about your sleep and ways that you can behave differently, which will reduce the things that are getting in the way of your sleep functioning the way that it should normally. I think when I talk to patients, and also when I do training with providers, I talk about how we can condition our bed to be associated with things other than sleep. So if we repeatedly snack in front of the tv, even though we've just had supper maybe a half an hour before, if we go and sit down in that chair that we always snack in, we're not hungry, but we find ourselves reaching for something to eat. The same thing can happen at night, where if you repeatedly pair your bed with things other than sleep, if you're thinking in bed, if you're planning, if you're worrying, if you're ruminating, if you know you're doing anything, if you're on your screen or you're watching tv or you're doing anything that's arousal producing, people can find that they're so tired, they're nodding off on the couch. They go up to bed, and all of a sudden, bang, they're wide awake and their mind is turning and they're thinking and they're like, “Why is this happening to me? I was just tired. I was so tired.” People with insomnia can relate to that very easily. That, “Oh, okay. So there's this conditioned association between my bed and wakefulness. How do I get rid of that?” That's where what we think and what we do around our sleep, we can change to be able to make our bed someplace that is strongly associated with sleep and not all of those other activities.  Dr. Davide Soldato: Thank you for the remarks on oncologists and sometimes our resistance to accept this type of intervention. I think that this also speaks to the merit of the Journal of Clinical Oncology, which publishes high level evidence also on symptom management, and these types of interventions that are, in the end, effective for our patients.  So I think that this concludes our interview for today. Thank you again, Dr. Garland for joining us.  Dr. Sheila Garland: Thank you Dr. Soldato. Dr. Davide Soldato: Dr. Garland, we appreciate you sharing more on your JCO article titled, “Randomized Controlled Trial of Virtually Delivered Cognitive Behavioral Therapy for Insomnia to Address Perceived Cancer-Related Cognitive Impairment in Cancer Survivors.” If you enjoy our show, please leave us a rating and review and be sure to come back for another episode. You can find all ASCO shows at asco.org/podcast. The purpose of this podcast is to educate and to inform. This is not a substitute for professional medical care and is not intended for use in the diagnosis or treatment of individual conditions.  Guests on this podcast express their own opinions, experience and conclusions. Guest statements on the podcast do not express the opinions of ASCO. The mention of any product, service, organization, activity or therapy should not be construed as an ASCO endorsement.      

What can you do today to improve or maintain your brain health? Join Sarah Banks, Ph.D., a leading expert in healthy aging, dementia, and Alzheimer's disease, and discover actionable steps you can take to protect your brain health. Series: "Stein Institute for Research on Aging" [Health and Medicine] [Show ID: 40061]

What can you do today to improve or maintain your brain health? Join Sarah Banks, Ph.D., a leading expert in healthy aging, dementia, and Alzheimer's disease, and discover actionable steps you can take to protect your brain health. Series: "Stein Institute for Research on Aging" [Health and Medicine] [Show ID: 40061]

What can you do today to improve or maintain your brain health? Join Sarah Banks, Ph.D., a leading expert in healthy aging, dementia, and Alzheimer's disease, and discover actionable steps you can take to protect your brain health. Series: "Stein Institute for Research on Aging" [Health and Medicine] [Show ID: 40061]

What can you do today to improve or maintain your brain health? Join Sarah Banks, Ph.D., a leading expert in healthy aging, dementia, and Alzheimer's disease, and discover actionable steps you can take to protect your brain health. Series: "Stein Institute for Research on Aging" [Health and Medicine] [Show ID: 40061]

What can you do today to improve or maintain your brain health? Join Sarah Banks, Ph.D., a leading expert in healthy aging, dementia, and Alzheimer's disease, and discover actionable steps you can take to protect your brain health. Series: "Stein Institute for Research on Aging" [Health and Medicine] [Show ID: 40061]

What can you do today to improve or maintain your brain health? Join Sarah Banks, Ph.D., a leading expert in healthy aging, dementia, and Alzheimer's disease, as she discusses the latest research on diet and cognitive decline. Learn how diet, vascular health and inflammation contributes to cognitive function and discover actionable steps you can take to protect your brain health. Stay informed and proactive about maintaining cognitive function as you age with insights from cutting-edge research. Series: "Stein Institute for Research on Aging" [Health and Medicine] [Show ID: 40063]

What can you do today to improve or maintain your brain health? Join Sarah Banks, Ph.D., a leading expert in healthy aging, dementia, and Alzheimer's disease, as she discusses the latest research on diet and cognitive decline. Learn how diet, vascular health and inflammation contributes to cognitive function and discover actionable steps you can take to protect your brain health. Stay informed and proactive about maintaining cognitive function as you age with insights from cutting-edge research. Series: "Stein Institute for Research on Aging" [Health and Medicine] [Show ID: 40063]

What can you do today to improve or maintain your brain health? Join Sarah Banks, Ph.D., a leading expert in healthy aging, dementia, and Alzheimer's disease, as she discusses the latest research on diet and cognitive decline. Learn how diet, vascular health and inflammation contributes to cognitive function and discover actionable steps you can take to protect your brain health. Stay informed and proactive about maintaining cognitive function as you age with insights from cutting-edge research. Series: "Stein Institute for Research on Aging" [Health and Medicine] [Show ID: 40063]

What can you do today to improve or maintain your brain health? Join Sarah Banks, Ph.D., a leading expert in healthy aging, dementia, and Alzheimer's disease, as she discusses the latest research on diet and cognitive decline. Learn how diet, vascular health and inflammation contributes to cognitive function and discover actionable steps you can take to protect your brain health. Stay informed and proactive about maintaining cognitive function as you age with insights from cutting-edge research. Series: "Stein Institute for Research on Aging" [Health and Medicine] [Show ID: 40063]

What can you do today to improve or maintain your brain health? Join Sarah Banks, Ph.D., a leading expert in healthy aging, dementia, and Alzheimer's disease, as she discusses the latest research on diet and cognitive decline. Learn how diet, vascular health and inflammation contributes to cognitive function and discover actionable steps you can take to protect your brain health. Stay informed and proactive about maintaining cognitive function as you age with insights from cutting-edge research. Series: "Stein Institute for Research on Aging" [Health and Medicine] [Show ID: 40063]

What can you do today to improve or maintain your brain health? Join Sarah Banks, Ph.D., a leading expert in healthy aging, dementia, and Alzheimer's disease, as she discusses the latest research on diet and cognitive decline. Learn how diet, vascular health and inflammation contributes to cognitive function and discover actionable steps you can take to protect your brain health. Stay informed and proactive about maintaining cognitive function as you age with insights from cutting-edge research. Series: "Stein Institute for Research on Aging" [Health and Medicine] [Show ID: 40063]

What can you do today to improve or maintain your brain health? Join Sarah Banks, Ph.D., a leading expert in healthy aging, dementia, and Alzheimer's disease, as she discusses the latest research on diet and cognitive decline. Learn how diet, vascular health and inflammation contributes to cognitive function and discover actionable steps you can take to protect your brain health. Stay informed and proactive about maintaining cognitive function as you age with insights from cutting-edge research. Series: "Stein Institute for Research on Aging" [Health and Medicine] [Show ID: 40063]

What's the deal with statin drugs and “high cholesterol”? Even doctors are starting to raise questions. They say that “high cholesterol” is anything over 200 total, but where does this number come from? Is there evidence that cholesterol over 200 actually leads to heart disease? Why do we need cholesterol, and is it possible for it to get too low? On this episode of Vitality Radio Jared arms you with the information you need to decide what to do, if anything, about your “high” cholesterol.  Pharmaceutical companies often develop drugs that target specific symptoms by interfering with the body's natural processes. These medications can be effective in providing temporary relief from symptoms, but they don't usually address the underlying causes of a condition. This is called suppressive medicine, and such treatments may offer short-term benefits at the cost of long-term health. In this series of episodes on suppressive medicine, Jared aims to help you understand the ways in which these drugs work and what natural alternatives there are that work WITH your body's natural systems to address the root cause and rebalance the body. Products:BerberineAdditional Information:#332: Cholesterol Controversy - Jared's Interview on Inside The Aisle with Niki WolfeVisit the podcast website here: VitalityRadio.comYou can follow @vitalityradio and @vitalitynutritionbountiful on Instagram, or Vitality Radio and Vitality Nutrition on Facebook. Join us also in the Vitality Radio Podcast Listener Community on Facebook. Shop the products that Jared mentions at vitalitynutrition.com. Let us know your thoughts about this episode using the hashtag #vitalityradio and please rate and review us on Apple Podcasts. Thank you!Please also join us on the Dearly Discarded Podcast with Jared St. Clair.Just a reminder that this podcast is for educational purposes only. The FDA has not evaluated the podcast. The information is not intended to diagnose, treat, cure, or prevent any disease. The advice given is not intended to replace the advice of your medical professional.

In the second part of this series, Drs. Henry A. Nasrallah and Dawn Velligan continue sharing their insights into the importance of assessing and screening for cognitive impairment in patients with schizophrenia. They discuss why testing for cognitive impairment in standard clinical practice isn't more widespread, the barriers clinicians face in testing, and the misconception that testing for cognitive impairment is prohibitive due to the resources required. Finally, they describe time factors and utility of several currently available tests, including those that can be used in busy ambulatory mental healthcare settings.

Drs. Dawn Velligan and Henry A. Nasrallah share their insights into the importance of assessing and screening for cognitive impairment in patients with schizophrenia. They discuss why testing for cognitive impairment in standard clinical practice isn't more widespread, the barriers clinicians face in testing, and the misconception that testing for cognitive impairment is prohibitive due to the resources required. Finally, they describe time factors and utility of several currently available tests, including those that can be used in busy ambulatory mental healthcare settings.

What if I told you that a single biochemical process could be the key to unlocking your body's full potential? In this eye-opening episode of The Dr. Josh Axe Show, we dive deep into the world of methylation - a crucial process affecting over 40% of Americans. Dr. Axe breaks down this complex topic, revealing how it impacts everything from your mood to your ability to detoxify. Tune in to discover: The 'sticky note' analogy that makes understanding methylation a breeze Why poor methylation could be behind your unexplained fatigue, brain fog, or mood swings The shocking connection between methylation and your risk of heart disease and autoimmune disorders Nature's top methylation boosters - including one surprising food that outperforms all others How your gut health might be the secret key to optimizing your methylation pathway The MTHFR gene variant: what it means and why you should care Simple, actionable steps to support your body's methylation process starting today Whether you're a health enthusiast or struggling with unexplained symptoms, this episode is a must-listen. Dr. Axe delivers complex information in an easy-to-understand format, equipping you with the knowledge to take control of your health. By the end of this show, you'll have a clear understanding of methylation and a practical toolkit to optimize this vital process in your body. Don't miss out on this game-changing information - your cells will thank you! Want more of The Dr. Josh Axe Show? Subscribe to the YouTube channel. Follow Dr. Josh Axe Instagram Twitter Facebook Tik-Tok ------  Links:  Ferira, L. (2021). "The Role of Methylation in Human Health." Journal of Nutrition. Rountree, R. (2020). "Environmental Impacts on Methylation." Environmental Health Perspectives. Masterjohn, C. (2022). "Riboflavin and Its Importance for Methylation." Nutritional Biochemistry. CDC (2023). "Antibiotic Resistance and Usage Statistics." WHO (2022). "COVID-19 and Antibiotic Usage." Smith, A. D., & Refsum, H. (2016). "Homocysteine, B Vitamins, and Cognitive Impairment." Annual Review of Nutrition. Watanabe, F., & Yabuta, Y. (2013). "Vitamin B12 Sources and Bioavailability." Food and Nutrition Bulletin. Bailey, L. B., & Gregory, J. F. (2011). "Folate and Other Methyl Donors: Effects on the Risk of Cardiovascular Disease." Current Opinion in Lipidology. Pinna, K. L. (2018). "Probiotics and Gut Health: Mechanisms and Applications." Frontiers in Microbiology. Ulta Labs. (2023). "MTHFR Gene Variation Testing and Homocysteine Testing."

Can a new drug slow the progression of Alzheimer's disease? Find out about this and more in today's PeerDirect Medical News Podcast.

Dr. Eduardo Fernández and Dr. Daniel Weintraub discuss whether subjective cognitive complaints can predict future incident cognitive impairment and other questions related to early cognitive impairment in people with Parkinson's disease, referencing Dr. Weintraub's recent article, "Association between subjective cognitive complaints and incident functional impairment in Parkinson's disease" published in Movement Disorders. Read article »

Dr. Halley Alexander discusses the Neurology Today article, "Prospective Study Presents Longitudinal Trajectory of Cognitive Impairment in Patients With Essential Tremor" by Susan Kreimer, available in the June 20th issue of Neurology Today or at neurologytoday.com.  Show reference:  https://journals.lww.com/neurotodayonline/fulltext/2024/06200/prospective_study_presents_longitudinal_trajectory.2.aspx This podcast is sponsored by argenx. Visit www.vyvgarthcp.com for more information.

Short on time? You can still screen for these function-limiting symptoms. Credit available for this activity expires: 6/26/25 Earn Credit / Learning Objectives & Disclosures: https://www.medscape.org/viewarticle/1001208?ecd=bdc_podcast_libsyn_mscpedu

Can the use of hearing aids slow down cognitive decline? Find out about this and more in today's PeerDirect Medical News Podcast.

Another front page story from a national newspaper...The Boston Globe...Provides a first hand story of a mother and wife told from the perspective of her husband and high school sweet heart. I share this story for the same reason as the last story I did. That one from the New York Times. There is much you can do to support. To increase the likelihood of improvement in a person. Please see this as a hand to help 'Step Up' and not sit passively by to watch your loved ones wither away. This is very much for you personally as well. Time to be proactive and preventative and not passively sitting back waiting for the next new medication to help you. Maybe that will happen but in the meantime, get involved proactively and learn what you can.  START HERE and continue. Always ask questions, be assertive, make alliances, and research...and think for yourself. It's really on you.Links:How could my wife have Alzheimer's? She was only 56 1-7-2022 https://www.bostonglobe.com/2020/01/07/magazine/my-wife-couldnt-have-alzheimers-she-was-only-56/?p1=Article_Recirc_Most_Popular—————————COME SAY HI!!! —————————— Facebook Group about Keto: https://www.facebook.com/groups/ketonaturopath/ BLOG: https://ketonaturopath.com/ Pinterest: https://www.pinterest.com/ketonaturopath YYouTube channel www.youtube.com/ketonaturopath Podcast: https://www.buzzsprout.com/482971/episodes Our Youtube Podcasts https://studio.youtube.com/channel/UC6LBX8_RDaXtzF_Z02jvl0QJudi's NEW cooking channel Keto Naturopath Kitchen https://www.youtube.com/c/KetoNaturopathKitchen       ——————————— OUR COURSE —————————— PSMF 30 day course: https://www.thebiointegrationcode.com/courses/PSMFChallenge————WHERE WE GET OUR GENOME SNP ANALYSIS DONE—————Strategene https://bit.ly/3iqCfka ——————————WHERE WE GET YOUR LABS DONE—————https://www.UltaLabTests.com/ketonaturopath ————————— WHERE WE BUY OUR SUPPLEMENTS ——————https://us.fullscript.com/welcome/drgoldkamp/signupWhy get a Fullscript account to get your supplements?? 1. They have more brands than anywhere else to choose from; 2. Their prices are 20 -50% lower than anywhere else; compare and you'll see 3. This is where most physicians have their account 4. Been in existence for nearly 30 years working with physicians and health practitioners sustained outcomes in the end.

Join us as we explore the significance of cognitive assessments in early detection and understand how these assessments can be a game-changer in identifying cognitive impairment. guest: Tom O'Neill, CEO of Cognivue Learn more about Cognivue: https://cognivue.com/ --- Normalize The Conversation by Inspiring My Generation is an initiative of Inspiring My Generation. Inspiring My Generation is a 501(c)3 on a mission of suicide prevention through awareness, conversation, empowerment, and support (aces). --- Send in a voice message: https://podcasters.spotify.com/pod/show/normalizetheconversation/message Support this podcast: https://podcasters.spotify.com/pod/show/normalizetheconversation/support

This presentation was delivered by Jeremy Pallas as part of the Trauma Updates Workshop at CODA22, which took place in Melbourne in September 2022.  For more information about the CODA Project go to: https://codachange.org/ 

My new book Reframe Your Brain, available now on Amazon https://tinyurl.com/3bwr9fm8 Find my "extra" content on Locals: https://ScottAdams.Locals.com Content: Politics, SOTU Review, President Biden, IVF Opposition, Democrat Policy Preferences, 25% Billionaire Tax, Cognitive Impairment, Paul Krugman, Katie Britt SOTU, Tucker Carlson SOTU, Voter ID, Loneliness Depression Crisis, TikTok Ban, Rand Paul, Body Language Lie Detection, FDA LSD Trials, Anxious Incompetent Kids, Scott Adams ~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~ If you would like to enjoy this same content plus bonus content from Scott Adams, including micro-lessons on lots of useful topics to build your talent stack, please see scottadams.locals.com for full access to that secret treasure. --- Support this podcast: https://podcasters.spotify.com/pod/show/scott-adams00/support